



ENFORTUMAB VEDOTIN

An investigational antibody-drug conjugate directed to Nectin-4

Anti-Nectin-4 antibody


Fully human monoclonal antibody that binds to Nectin-4

MMAE

Microtubule-disrupting agent

Protease-cleavable mc-vc linker

Covalently attaches MMAE to the antibody and releases agent within the target cell



Nectin-4

- Highly expressed in urothelial carcinoma and certain other solid malignancies, with low-to-moderate expression in normal tissue^{1,2}
- High expression of Nectin-4 is associated with poor prognosis in select solid malignancies³

mc-vc: maleimidocaproyl-valine-citrulline; MMAE: monomethyl auristatin E

1. Challita-Eid PM. Cancer Res. 2016: 3003-13. 2. Boylan KLM. Oncotarget. 2017: 9717-38. 3. Zhang Y. Cancer Lett. 2016: 179-89.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.



Scan to learn more about the proposed mechanism of action of enfortumab vedotin

Clinical Trials^a

Phase 1 Phase 2 Phase 3

	RECRUITING^b	EV-302/KEYNOTE-A39^c: Untreated locally advanced or mUC (NCT04223856) Enfortumab vedotin + pembrolizumab vs chemotherapy
	RECRUITING	KEYNOTE-905/EV-303^d: MIBC, ineligible for/decline cisplatin (NCT03924895) Perioperative pembrolizumab ± enfortumab vedotin + RC + PLND vs RC + PLND alone
	RECRUITING	KEYNOTE-B15/EV-304^d: Cisplatin-eligible MIBC (NCT04700124) Perioperative enfortumab vedotin + pembrolizumab + RC + PLND vs neoadjuvant chemotherapy + RC + PLND
	ACTIVE, NOT RECRUITING	EV-202: Locally advanced or metastatic malignant solid tumors (NCT04225117) Enfortumab vedotin alone
	RECRUITING	KEYMAKER-U04^{e,g}: First-line locally advanced or metastatic urothelial cancer (NCT05845814) Enfortumab vedotin + pembrolizumab ± other agents
	ACTIVE, NOT RECRUITING	EV-103/KEYNOTE-869^{f,h}: Urothelial cancer (NCT03288545) Enfortumab vedotin alone or with other therapies
	RECRUITING	EV-104: Non-muscle invasive bladder cancer (NCT05014139) Intravesical enfortumab vedotin alone

MIBC: muscle invasive bladder cancer; mUC: metastatic urothelial cancer; RC + PLND: radical cystectomy plus pelvic lymph node dissection

^aProgram being co-developed with Astellas Pharma Global Development, Inc.

^bEnrolling in a China-specific extension only

^cStudy sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD)

^dStudy sponsored by MSD, in collaboration with Seagen Inc. and Astellas Pharma Global Development, Inc.

^eStudy sponsored by MSD; Substudy 04B of KEYMAKER-U04 umbrella study

^fStudy sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and MSD

^gPhase 1/2

^hPhase 1b/2

Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Astellas and the flying star logo are registered trademarks of Astellas Pharma Global Development, Inc. Seagen and its logo are US registered trademarks of Seagen Inc. Other trademarks are property of their respective owners.

© 2023 Seagen Inc., Bothell, WA 98021; Astellas Pharma Global Development, Inc., Northbrook, IL 60062
Printed in the USA MA-MM-07216 Oct 2023

For more information, contact us at:
+1-855-4SEAGEN (+1-855-473-2436)
medinfo@seagen.com / medinfoEU@seagen.com
www.seagenmedinfo.com